

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A method for treating a patient suffering from liver cancer or liver metastases in need of a drug metabolized primarily by CYP3A, which comprises detecting CYP3A levels in a patient patients suffering a liver cancer or a liver metastases; and administering a therapeutically effective amount of nemorubicin, based on said detected CYP3A levels, to those patients whose CYP3A levels indicate formation of a metabolite of nemorubicin more active than nemorubicin.
2. (Cancelled)
3. (Currently Amended) A method ~~for of~~ optimizing the therapeutic efficacy of nemorubicin in the treatment of a liver cancer or a liver metastases patient in need thereof, which comprises predicting the sensitivity of the a patient suffering a liver cancer or a liver metastases towards nemorubicin through the detection of CYP3A levels in a biological sample of said patient and selecting a therapeutically effective amount of said nemorubicin based on said CYP3A levels.
4. (Cancelled)
5. (Currently Amended) A method ~~for of~~ treating a liver cancer or a liver metastases sensitive to nemorubicin, which comprises:

- (a) obtaining a biological sample from a patient suffering from a liver cancer or a liver metastases sensitive to nemorubicin;
- (b) detecting the amount of CYP3A levels in said sample;
- (c) selecting a therapeutically effective amount of said nemorubicin based on said CYP3A levels; and
- (d) administering said therapeutically effective amount of said nemorubicin to said patient.

6. (Cancelled)

7. (Currently Amended) A method ~~for of~~ predicting a patient's sensitivity to nemorubicin in a patient suffering a liver cancer or a liver metastases comprising determining levels of CYP3A in a patient suffering a liver cancer or a liver metastases and wherein said patient's sensitivity to said nemorubicin is effected determined by said CYP3A levels activity.

8.-10. (Cancelled)

11. (Previously Presented) The method of Claim 1 wherein said detection of said CYP3A levels is obtained by an erythromycin breath test.

12. (Previously Presented) The method of Claim 3 wherein said detection of CYP3A levels is obtained by an erythromycin breath test.

13. (Previously Presented) The method of Claim 5 wherein said detection of CYP3A levels is obtained by an erythromycin breath test.

14. (Currently Amended) The method of Claim 7 wherein said detection determination of said CYP3A levels is obtained by an erythromycin breath test.